NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

anti-FCRH5/CD3 BiTE antibody BFCR4350A
A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of anti-FCRH5/CD3 BiTE antibody BFCR4350A, the bispecific antibody binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-FCRH5 × anti-CD3 bi-specific T-cell engager BFCR4350A
anti-FCRH5/CD3 TDB BFCR4350A
FCRH5/CD3 T cell-dependent bispecific antibody BFCR4350A
FCRH5/CD3 TDB antibody BFCR4350A
recombinant anti-FCRH5 × anti-CD3 bi-specific T-cell engager BFCR4350A
Code name:BFCR4350A